Banner - NPPA Connect
NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Artificial Intelligence
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Paul Yamauchi, MD, PhD

Advertisement

Articles by Paul Yamauchi, MD, PhD

New Research Confirms Effective Therapy for Nail Psoriasis

ByMaddi Hebebrand, MC, Associate Editor,Paul Yamauchi, MD, PhD
March 20th 2025

Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.

Advertisement

Latest Updated Articles

  • New Research Confirms Effective Therapy for Nail Psoriasis
    New Research Confirms Effective Therapy for Nail Psoriasis

    Published: March 20th 2025 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows

2

Targeting MRGPRX2: Early Human Data for a Novel CSU Approach

3

What Counts as “Short-Term” Systemic Corticosteroids in Atopic Dermatitis, and Why It Matters

4

New Phase 3 DISCREET Data Supports Long-Term Use of Apremilast for Genital Psoriasis

5

Phase 3 Results Signal a New Era for Oral Targeted Therapy in Psoriasis

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us